A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase 1
Terminated
- Conditions
- Unresectable MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04625205
- Locations
- π§πͺ
Universitair Ziekenhuis Brussel, Brussel, Belgium
π³π±Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
Phase 1
Terminated
- Conditions
- Metastatic Melanoma
- Interventions
- Biological: NEO-PV-01Biological: NivolumabOther: AdjuvantBiological: ipilimumabBiological: APX005M
- First Posted Date
- 2018-07-24
- Last Posted Date
- 2020-09-03
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT03597282
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈUniversity of California, Los Angeles, Los Angeles, California, United States
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
Phase 1
Completed
- Conditions
- Carcinoma, Non-Small-Cell LungLung CancerNonsquamous Nonsmall Cell Neoplasm of Lung
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03380871
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈSarah Cannon Research Institute, Nashville, Tennessee, United States
A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Phase 1
Completed
- Conditions
- Urinary Bladder CancerBladder TumorsMelanomaTransitional Cell Carcinoma of the BladderMalignant MelanomaCarcinoma, Non-Small-Cell LungSkin CancerLung Cancer
- Interventions
- Biological: NEO-PV-01Biological: NivolumabOther: Adjuvant
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT02897765
- Locations
- πΊπΈ
City of Hope, Duarte, California, United States
πΊπΈUCLA Medical Center, Los Angeles, California, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
Β© Copyright 2025. All Rights Reserved by MedPath